pharma · Retinitis Pigmentosa · Dry Eye Disease · KPRX
KIORA PHARMACEUTICALS
KIORA PHARMACEUTICALS INC
Kiora Pharmaceuticals is a pharma organization headquartered in Encinitas, USA. It trades on NYSE under ticker KPRX. Primary therapeutic focus areas include Retinitis Pigmentosa, Dry Eye Disease, Macular Edema, Persisten
Encinitas, USA HQ
2013 Founded
18 Employees
Public company Type
KPRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Encinitas, USA
- Founded
- 2013
- Employees
- 18
- Programs
- 5
- Drugs
- 4
- Patents
- 4
OBG PED-001
Phase 2 · small molecule · Persistent Corneal Epithelial Defect
OBG PED-001 for Persistent Corneal Epithelial Defect is a Phase 2 program (small_molecule) at KIORA PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Internal code OBG PED-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- KIORA PHARMACEUTICALS INC
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Persistent Corneal Epithelial Defect
- Status
- completed
- Trials
- 1